Quetiapine Misuse and Abuse: Is It an Atypical Paradigm of Drug Seeking Behavior? by Kim, Sean Hyungwoo et al.
University of Kentucky 
UKnowledge 
Institute for Pharmaceutical Outcomes and 
Policy Faculty Publications Pharmaceutical Outcomes and Policy 
2-27-2017 
Quetiapine Misuse and Abuse: Is It an Atypical Paradigm of Drug 
Seeking Behavior? 
Sean Hyungwoo Kim 
University of Kentucky, sean.kim@uky.edu 
Gayoung Lee 
Johns Hopkins University 
Eric Kim 
University of Alabama, Birmingham 
Hyejin Jung 
University of Texas, El Paso 
Jongwha Chang 
University of Texas, El Paso, jchang@utep.edu 
Follow this and additional works at: https://uknowledge.uky.edu/ipop_facpub 
 Part of the Pharmacy Administration, Policy and Regulation Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Kim, Sean Hyungwoo; Lee, Gayoung; Kim, Eric; Jung, Hyejin; and Chang, Jongwha, "Quetiapine Misuse and 
Abuse: Is It an Atypical Paradigm of Drug Seeking Behavior?" (2017). Institute for Pharmaceutical 
Outcomes and Policy Faculty Publications. 1. 
https://uknowledge.uky.edu/ipop_facpub/1 
This Article is brought to you for free and open access by the Pharmaceutical Outcomes and Policy at UKnowledge. 
It has been accepted for inclusion in Institute for Pharmaceutical Outcomes and Policy Faculty Publications by an 
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
Quetiapine Misuse and Abuse: Is It an Atypical Paradigm of Drug Seeking 
Behavior? 
Digital Object Identifier (DOI) 
https://doi.org/10.4103/2279-042X.200987 
Notes/Citation Information 
Published in Journal of Research in Pharmacy Practice, v. 6, issue 1, p. 12-15. 
© 2017 Journal of Research in Pharmacy Practice 
This is an open access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work 
non-commercially, as long as the author is credited and the new creations are licensed under the identical 
terms. 
This article is available at UKnowledge: https://uknowledge.uky.edu/ipop_facpub/1 
12  2017 Journal of Research in Pharmacy Practice | Published by Wolters Kluwer - Medknow
Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug 
Seeking Behavior?
Sean Kim1, Gayoung Lee2, Eric Kim3, Hyejin Jung4, Jongwha Chang5
Access this article online
Quick Response Code:
Website: www.jrpp.net
DOI: 10.4103/2279-042X.200987
Review Article
1Institute of Pharmaceutical 
Outcomes and Policy, 
University of Kentucky, 
Lexington, Kentucky, USA
2Wolfe Harry Feinstone 
Department of Molecular 
Microbiology and 
Immunology, Johns Hopkins 
University, Baltimore, USA
3Department of Biology, 
University of Alabama, 
Birmingham, Alabama, USA
4Department of Social Work, 
University of Texas, El Paso, 
Texas, USA
5Department of Pharmacy 
Practice, University of Texas, 
El Paso, Texas, USA
Address for correspondence: 
Prof. Jongwha Chang, E-mail: jchang@utep.edu
This is an open access article distributed under the terms of the Creative Commons 
Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, 
and build upon the work non-commercially, as long as the author is credited and the new 
creations are licensed under the identical terms. 
For reprints contact: reprints@medknow.com
How to cite this article: Kim S, Lee G, Kim E, Jung H, Chang J. Quetiapine 
misuse and abuse: Is it an atypical paradigm of drug seeking behavior?. 
J Res Pharm Pract 2017;6:12-5.
Recent case reports in medical literatures suggest that more and more second-generation 
atypical antipsychotics (AAs) have been prescribed for off-label use; quetiapine (Brand 
name: Seroquel®) showed increase in its trend for off-label use. Little is known about the 
reasons behind this trend, although historical sedative and hypnotic prescription patterns 
suggest that despite relatively superior safety profiles of quetiapine (especially for movement 
disorders), it may be used for treating substance abuse disorder. In addition, recent studies 
have shown a strong potential for misuse and abuse (MUA) of quetiapine beyond Food 
and Drug Administration-approved indications. This includes drug-seeking behaviors, such 
as feigning symptoms, motivated by quetiapine and use of quetiapine in conjunction with 
alcohol. Quetiapine appears to be the most documented AA with street values bartered illicitly 
on the street. A recent report from the Drug Abuse Warning Network has shown a high 
prevalence of quetiapine-related emergency department visits involving MUA. Several other 
case studies have found that quetiapine causes seeking behaviors observed in substance use 
disorder. In fact, the majority of quetiapine MUA involved patients diagnosed with substance 
use disorder. In the absence of a definitive mechanism of action of quetiapine’s reinforcing 
properties, it is imperative to gather robust evidence to support or refute increasing off-label 
use of AAs.
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IntroductIon
A typical antipsychotics (AAs), also known as second-generation antipsychotics, are a group of 
antipsychotic medications used to treat serious mental 
illness such as bipolar disorder, schizophrenia, and 
anxiety disorder.[1] Currently, there are 11 commonly 
prescribed AA medications approved by the Food and Drug 
Administration (FDA): aripiprazole, asenapine, clozapine, 
iloperidone, lurasidone, olanzapine, olanzapine/fluoxetine, 
paliperidone, quetiapine, risperidone, and ziprasidone.[1] 
Since the introduction of the first AA drug, clozapine, in the 
1970s, the advent of AAs has provided new treatment options 
for patients with serious psychiatric conditions.[2‑4] AAs are 
often considered safer than typical antipsychotics, they are 
associated with a decreased risk of neuroleptic malignant 
syndrome and extrapyramidal symptoms such as tardive 
dyskinesia (a movement disorder), tremor, and dystonia 
(muscle spasm and contractions).[1,5]
Recently, increasing off-label use of AAs outside 
FDA-approved indications has been evident.[1] In 2013, the 
Drug Utilization Sub-committee of Australian Department 
of Health showed evidence of antipsychotic use among 
people aged 20–59 for the treatment of conditions other 
than schizophrenia or bipolar disorder.[6] In the same year, 
the National Prescribing Service identified issues with 
off-label use of antipsychotics as means of behavior control 
in people with dementia in residential aged-care and other 
specialized-care facilities.[7]
A series of case reports of AA abuse was reported in literature 
more than a decade ago,[8,9] and several studies documented 
quetiapine as the most commonly abused AA.[10‑13] Although 
off-label prescribing in psychiatry is a common practice, 
changing trends in AA off-label use and the associated risks 
need to be scrutinized due to a potential correlation between 
previous substance abuse history (i.e., schizophrenia or 
bipolar disorder) and likelihood of misusing and abusing 
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AAs.[14,15] Use of AAs in patients with substance abuse has 
been noted where drug-seeking behaviors were observed in 
correctional facility settings.[10] Quetiapine abuse may be 
more prevalent among prisoners since commonly abused 
drugs are not readily available due to limited pharmaceutical 
formulary.[10]
Misuse and abuse (MUA) of pharmaceuticals is associated with 
medications that produce euphoria or other desirable effects 
such as relaxation or alertness.[16] Therefore, AAs are not 
generally considered drugs of abuse. However, AAs are being 
used to either enhance the effects of illicit substances such as 
cocaine and marijuana or counter their adverse effects.[17]
QuetIapIne In the treatment of substance 
abuse
AAs are commonly prescribed to aid in treating withdrawal 
symptoms from abused substances (i.e., alcohol, cocaine, 
benzodiazepines, or opioids) while increasing abstinence. 
However, this treatment showed inconsistent evidence 
with varying degrees of success.[18‑22] Quetiapine decreased 
psychiatric symptoms such as sleeplessness and anxiety for 
alcoholic patients with comorbid conditions such as bipolar 
disorder or schizoaffective disorder when patients were 
provided with 300–800 mg/day for 16 weeks following 
detoxification treatment.[14] One possible speculation is that 
quetiapine alleviated mood symptoms and anxiety associated 
with withdrawal symptoms.
It is interesting to note that when patients do not have 
comorbid psychiatric conditions, AAs used to treat 
substance abuse did not show any significant benefit versus 
placebo.[1] One possible explanation is that high comorbidity 
rate is thought to originate from the common biological roots 
of schizophrenia and bipolar disorders. Dopamine sensitivity 
in schizophrenic patients was found to make them more 
susceptible to the rewarding effect of the substance.[14]
QuetIapIne off‑label use
The use of AAs in clinical practice has extended beyond 
FDA-approved indications and off-label uses; there have been 
signs that corroborate the emergence of quetiapine as the 
most commonly abused AA.[23] These signs include existence 
of street names and values in the black market, diversion 
in prisons and other institutionalized settings, users seeking 
drug by feigning symptoms, and reports of intravenous or 
intranasal use of the drug.[16] Some street names include 
“Susie-Q,” “baby-heroin,” and “squirrel,” when used 
in conjunction with other drugs of abuse, combinations 
are referred to as Maq‑ball (quetiapine + marijuana) or 
Q‑ball (quetiapine + cocaine or heroin).[10,13,24,25] Numerous 
early reports and case studies focused on illicit use in 
incarcerated populations, which are at high risk of quetiapine 
MUA.[11-13] In most cases, MUA of AAs are shown to be 
associated with forensic settings such as incarceration, 
court-ordered hospitalization, or other oversight by the legal 
system. Numerous case reports and several systematic studies 
have shown that quetiapine MUA is not confined to penal 
populations; it also occurs in other settings such as psychiatric 
inpatients, outpatients, and patients attending drug treatment 
clinics.[14,25,26]
Although the magnitude of AA MUA is unclear, this emerging 
trend has gained recognition. Patients often misuse AAs in an 
attempt to self-medicate and ameliorate unpleasant symptoms 
of withdrawal. Substance abusers may take AAs to counteract 
the effects of the addicted agent. In addition, polydrug users 
who were prescribed numerous psychoactive drugs are 
associated with illegally obtaining quetiapine in combination 
with other drugs.[27‑29]
QuetIapIne abuse and adVerse health 
outcomes
Quetiapine abuse is most frequently related to its sedative and 
anxiolytic characteristics.[10] It is proposed that the motivation 
for quetiapine MUA is “self-medication” for symptoms of 
anxiety and sleep withdrawal rather than euphoric effects.[14] 
Nationally representative data presented by a recent study 
of emergency department (ED) visits involving MUA of 
quetiapine further highlight this emerging trend. The Drug 
Abuse Warning Network (DAWN) has contributed evidence 
stating MUA of quetiapine is warranted.[16] The study found 
that high frequency of quetiapine-related ED visits involving 
MUA occurs among the noninstitutionalized general 
population, suggesting the need for evaluating potential MUA 
of quetiapine by patients.[16]
There is a growing concern within the medical community in 
regard to the potential harm from prescribing quetiapine for its 
off-label use as well as dependence potential. In addition, there 
have been a number of international high‑profile court cases in 
the media regarding quetiapine-related death involving either 
drug-drug interactions or overdose.[6,30] Little is known about 
the reasons for off-label prescribing, but a historical perspective 
of sedative and hypnotic prescribing trends may explain this 
escalating use. The transition from barbiturates from early to 
mid‑20th century (1920–1950s) to benzodiazepines in the 1960s 
were mainly due to safety concerns.[24,31] Benzodiazepines use 
became more prevalent, but there have been increasing safety 
concerns over benzodiazepines, in particular alprazolam.[32] It is 
interesting to note that patients whose symptoms with insomnia 
may be able to benefit from sedating characteristic of 
second-generation antipsychotics. More importantly, long-term 
use of both benzodiazepines and barbiturates has shown 
dependence with withdrawal symptoms, tolerance, and 
drug-seeking behavior despite a maladaptive pattern of substance 
abuse.[33] Quetiapine, on the other hand, poses very low dystonia 
and extrapyramidal side effects. Hence, it is predicted that 
this seemingly safer profile is what makes quetiapine a more 
attractive treatment option than other antipsychotics. However, 
some known side effects such as metabolic disturbances such 
as weight gain, diabetes, and dyslipidemia are prominent in 
second-generation AAs.[34,35] Clozapine and olanzapine carry 
significantly higher risk than other AAs, whereas aripiprazole, 
lurasidone, and ziprasidone are associated with the lowest risk 
of metabolic disturbances.[36‑41]
[Downloaded free from http://www.jrpp.net on Monday, April 30, 2018, IP: 128.163.8.74]
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dIscussIon: publIc health ImplIcatIon
From a public health perspective, how does MUA of AAs pose 
a public health challenge? When AAs are used for recreational/
self-medication purposes without medical supervision, there 
are negative health consequences as MUA poses health risks 
as well as ED visits.[16] According to Mattson et al., ED visits 
involving MUA of quetiapine accounted for 52% of visits due 
to any antipsychotics. In addition, the greatest contributor to 
ED visits was quetiapine where 62% of visits were due to 
second-generation AAs.[33] These findings suggest the need for 
heightened vigilance on potential MUA of quetiapine as well 
as other AAs. In addition to personal health risks, quetiapine 
MUA may pose negative public health implications. Providing 
AAs to malingering individuals in forensic settings affects 
mental health budgets as well as our available public health 
resources. Injudicious prescription of quetiapine is a rising 
problem as health-care providers need to have tighter 
regulations and clinical guidelines to follow. There is a need 
to consider quetiapine as a potential candidate to be classified 
as a scheduled controlled substance if there are robust research 
findings in the future.[27,42]
Tarasoff and Osti suggest that there is evidence for quetiapine 
being commonly diverted from prescribed users for its 
cash street value.[29] Hence, clinicians need to be especially 
concerned about MUA when prescribing quetiapine to patients 
with comorbid mental health conditions for self-treating 
substance MUA as well as quetiapine’s potential for abuse. 
Clinicians should be aware of the fact that patients who 
are looking out for quetiapine should pay close attention to 
potential substance abuse and dependence. This emerging 
public health problem merits continued surveillance and 
awareness on the part of prescribers and the public health 
community of the potential for misuse of AAs.[16]
conclusIon
Quetiapine MUA is increasing due to the fact that 
clinicians are prescribing fewer benzodiazepines, 
barbiturates, and stimulant drugs because of their addictive 
characteristics.[14] Quetiapine has its unique motivation for 
anxiolytic and sedative effects without dependence. However, 
several case studies have found that quetiapine causes 
seeking behaviors observed in substance use disorder in the 
absence of definitive mechanism of action of quetiapine’s 
reinforcing properties. Therefore, it is imperative to gather 
robust evidence to support or refute increasing off-label use 
of AAs as well as dependence.
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